Search This Blog

Wednesday, February 6, 2019

Nanny State Hawaii May Increase Smoking Age To 100

The state government in Hawaii wants to increase the smoking age to 100.  Although pretty much everyone on Earth knows smoking is damaging to a person’s overall health, the nanny state is taking it upon themselves to ban the use of more substances.

Nothing good can ever come from the government dictating to people what they are allowed to put in their bodies, and that includes smoking.  Are we free or not? Do we own ourselves or not? Governments assume they own us as tax cattle and therefore it’s their right to tell us how to live our lives.  Unfortunately, too many bow down to the whims of the state while others enforce these nanny state policies.
If this bill succeeds in becoming a law, it would effectively ban the use of cigarettes for a very vast majority of the Hawaiian population. The bill was proposed by Democrat Richard Creagan, an obvious authoritarian. Even if it does become a law, laws hinge only on the population’s willingness to abide by them, so it could be futile much like prohibition was. Not to mention worldwide smoking rates are plummeting to people voluntarily making the decision that it isn’t good for them. According to the BBC, Creagan, who was an emergency room physician before he was elected as state representative in 2014, calls the cigarette “the deadliest artifact in human history” in the bill.
The new bill, HB 1509, demands that the smoking age go up to 30 in 2020, 40 in 2021, 50 in 2022, and 60 in 2023. The last jump will take place in 2024 when people would need to be 100 years old to buy cigarettes.
 “We don’t allow people free access to opioids, for instance, or any prescription drugs,” Creagan said in defense of his tyrannical bill.
And even though the government has banned opioids without a prescription, there’s an opioid addiction crisis lowering the life expectancy of Americans.  Prepare for a cigarette black market in Hawaii should Creagan get his way.

Mitochondrial dysfunction biotech Stealth sets terms for $81 million IPO

Stealth BioTherapeutics, a Phase 3 biotech focused on mitochondrial dysfunction, announced terms for its IPO on Wednesday.
The Newton, MA-based company plans to raise $81 million by offering 6.2 million ADSs at a price range of $12 to $14. Insiders intend to purchase $60 million worth of ADSs in the offering (74% of the deal).
At the midpoint of the proposed range, Stealth BioTherapeutics would command a fully diluted market value of $430 million.
Stealth BioTherapeutics was founded in 2006 and plans to list on the Nasdaq under the symbol MITO. Jefferies, Evercore ISI and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of February 11, 2019.

HHS official wants states to know the risks of pot legalization

The top HHS official in charge of preventing substance abuse called for a grassroots effort to inform states of the long-term health risks of marijuana as more states pursue legalization.
Dr. Elinore McCance-Katz, assistance secretary for mental health and substance use within HHS, implored attendees at the Substance Abuse and Mental Health Services Administration’s Prevention Day event to work with states on the health risks of marijuana. Katz, who heads up SAMHSA, said that marijuana today has a higher count of THC, the psychoactive ingredient in marijuana that creates its mind-altering effect, compared to 20 years ago.
“It is taking time to get attention to the issue, but you all can help with that,” McCance-Katz told the audience of addition prevention advocates and community leaders. “There has to be a huge sea change in order for this to be altered at this point.”
The THC count for marijuana in the 1990s was 4%, but it had increased to 12% in 2014, McCance-Katz said, citing a 2015 study.
“There are risks and adverse outcomes with marijuana, which are downplayed by the industry and ignored by our states,” she said. “There include low-birth weight babies, pulmonary systems, car crashes … and addiction.”
A recent study in Colorado found that after a nursing woman smokes marijuana once then her baby will consume traces of the drug through her breast milk for up to six weeks.
So far 33 states have approved laws to allow medical marijuana and nine states and the District of Columbia have legalized recreational use. Marijuana remains illegal under federal law, but neither the Trump nor Obama administrations enforced the law in states that legalized the drug for recreational use.
More states are considering legalization, with New York’s Legislature the latest to consider the issue.
An attendee asked McCance-Katz if the Trump administration was going to do anything to combat the rise of marijuana use and enforce federal laws. McCance-Katz responded that would be an issue for the Justice Department to consider.
“Marijuana is so incredibly prevalent now that from the perspective of a healthcare provider I am trying to help reduce the harm by informing people about the risk,” she said. “That is about as much as I can really say about it.”

Hospital price growth driving healthcare spending

Hospital prices are the main driver of U.S. healthcare spending inflation, and that trend should direct any policy changes going forward, according to a new study.
For inpatient care, hospital prices grew 42% from 2007 to 2014 while physician prices rose 18%, according to researchers who studied the Health Care Cost Institute’s claims data for people with employer-sponsored insurance from Aetna, Humana and UnitedHealthcare Group. Similarly, for hospital-based outpatient care, hospital prices increased 25% while physician prices grew 6%, the new Health Affairs study found.
Insurance costs a family of four about $19,000 a year. The reason costs vary so much across the country is because of the price of hospital care, which is the largest single component of healthcare costs in the U.S., said Zack Cooper, a study co-author and an associate professor of health policy at Yale University.
“What is most worrying to me is that there has been fairly profound consolidation among hospitals and when they gain market power they have the ability to raise prices,” he said. “They have the ability to gain more favorable contractual terms, which allows them to raise prices and resist the new, more sensible payment reforms.”
The U.S. healthcare economy is nearly as big as Germany’s entire economy. U.S. healthcare spending grew 3.9% to $3.5 trillion in 2017, consuming nearly 18% of the country’s gross domestic product, according to the CMS.
Higher healthcare spending limits economic growth. It stunts wages, produces higher out-of-pocket costs that dent disposable income and boosts federal subsidies for insurance bought through the Affordable Care Act exchanges.
About 33% of total healthcare spending is directed toward hospital care, translating to about 6% of total GDP, according to CMS data.
“If you look over the last 20 to 30 years, total employee compensation has gone up, but the amount each worker gets paid has been incredibly flat,” Cooper said. “The gains they would’ve gotten in income have gone toward paying their insurance and the largest chunk of that goes toward paying their local hospital.”
Healthcare inflation in the U.S. is projected to grow by an average of 5.5% annually from 2017 to 2026, ultimately reaching $5.7 trillion by 2026, the CMS estimates.
The common narrative is that growth in healthcare providers’ prices plays a larger role in driving growth in health spending on the privately insured than any change in case-mix or utilization. But to the researchers’ knowledge, this is the first analysis that systematically compared growth rates of hospital versus physician prices.
Researchers analyzed the pricing of four different hospital procedures—cesarean sections, vaginal deliveries, colonoscopies and knee replacements. The hospital component of the combined cost of care—physician plus hospital prices—ranged from 61% for vaginal deliveries to 84% for knee replacements.
Most of the growth in total price of care was driven by facility fees, which are higher rates meant to account for hospitals’ overhead. The growth in facility fees as a share of the growth in the combined cost of a service ranged from 77% for a colonoscopy to 97% for a knee replacement.
There were no systematic differences in results between hospitals that employed physicians and those that did not, researchers noted.
“We need to seriously think about regulating hospital prices,” Cooper said.
As an aside, researchers used negotiated prices from insurers aggregated through HCCI. Notably, the research institute recently announced that it will be losing UnitedHealth Group’s data in a move that experts characterized as a major blow to data transparency.
More care is shifting from the hospital to outpatient facilities and the home, which holds tremendous savings potential, Cooper said. But hospitals can reap similar profits when they acquire outpatient providers and physician groups.
A proposal to level payments for hospital-owned outpatient departments and independent offices could slow health systems’ acquisitions. But even with site-neutral payments, monopoly providers could still negotiate favorable contracts with payers, Cooper said.
Drug pricing has been the recent target of policymakers partially because out-of-pocket costs are typically higher. But hospital prices deserve a close look too, researchers outline.
A bill recently introduced in the California Legislature would allow state officials to cap hospital and physician prices. But broad-brush efforts could have unintended consequences, researchers warned. Policy solutions may need to be parceled out between the commercially insured and the Medicare fee-for-service beneficiaries, researchers argue in a related Health Affairs study.
Researchers recommended a range of options to rein in pricing, including antitrust enforcement, administered pricing and reference pricing as well as giving physicians incentives to make more cost-efficient referrals.
State and federal officials should scrutinize proposed mergers more vigorously, consider tougher remedies like divesting facilities when deals do go through, and block mergers that could raise prices. Massachusetts Attorney General Maura Healey’s mandate to cap price growth as a condition of the Beth Israel Deaconess Medical Center and Lahey Health merger was a step in the right direction, Cooper said.
“Hospitals have become some of the largest employers, so we face some tension between short-term politics and job numbers and the long-term vibrancy of these economies,” he said.
Regulating hospital payments, by tying them to Medicare rates for instance, could also help, researchers said. Private payers should consider reference pricing, which lets plan sponsors pay a fixed amount for a service, with members paying the difference in price for a higher-cost service.
Payers should give physicians incentives to refer their patients to hospitals that deliver the most efficient care. Vertical organizations like CVS Health and Aetna or UnitedHealth may direct more care outside of the hospital, Cooper said.
A new CMS requirement kicked in this year that forced hospitals to publish their lengthy list of retail charges for individual services and diagnosis-related groups. But that mandate was largely criticized by hospital executives and consumer advocates who argue that knowing the charges rather than the prices ultimately paid isn’t helpful.
“(Our study) is a guide for where policymakers should focus their efforts,” Cooper said.

Successful challenge of Biogen’s ‘514 patent unlikely, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $402 price target on Biogen (BIIB) after the latest filing disclosing that Mylan (MYL) petitioned U.S. PTAB to review its '514 patent covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in Biogen's Tecfidera label. The analyst notes that while the worst case scenario could remove about $50 per share from his sum-of-parts analysis on Biogen, he sees it as "unlikely", since the patent has been resilient to two prior challenges which were decided in Biogen's favor.
https://thefly.com/landingPageNews.php?id=2860515

Amicus to hold a conference call

Conference call to discuss the clinical Pompe disease data and pre-clinical Batten disease data presented at the WORLDSymposium will be held on February 6 at 7 pm.

Antidepressant Overprescribing Appears Common in Elderly

Potential antidepressant overprescribing appears to be common among elderly patients and involves mostly newer antidepressants used for nonspecific psychiatric symptoms and subthreshold diagnoses, according to a study published online Jan. 23 in Pharmacology Research & Perspectives.
William V. Bobo, M.D., M.P.H., from the Mayo Clinic in Jacksonville, Florida, and colleagues used data from the Rochester Epidemiology Project medical records-linkage system to assess new antidepressant prescriptions for elderly residents of Olmsted County, Minnesota (2005 to 2012). Health records were reviewed to identify indications for the prescriptions.
The researchers found that potential antidepressant overprescribing occurred in 24 percent of 3,199 incident antidepressant prescriptions during the study period. The suspected overprescribing involved primarily newer antidepressants that were prescribed for nonspecific psychiatric symptoms and subthreshold diagnoses. Factors associated with potential antidepressant overprescribing included nursing home residence; a higher number of comorbid medical conditions and outpatient prescribers; more concomitant medications; greater use of urgent or acute care services in the year preceding the index antidepressant prescription; and being prescribed antidepressants via telephone, email, or patient portal.
“When overprescribing occurred, it was associated with factors representing higher multimorbidity, clinical complexity, and severity — and with antidepressant prescribing that did not involve face-to-face interaction of patients with prescribers,” the authors write.